Collagen News and Research

Latest Collagen News and Research

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

Loyola University Health System is among the first centers to offer a new, nonsurgical treatment for Dupuytren's contracture, a debilitating condition that curls fingers toward the palm.

19 Jan 2011

pH Advantage adds Pyranase to facial skin care line

pH Advantage LLC recently added a new breakthrough product to its highly effective facial skin care line. Pyranase is clinically proven to reverse the signs of aging, reduce fine lines and wrinkles and improve the overall texture and appearance of the skin. Pyranase brings the proven effectiveness of a class of plant growth factor (cytokinin) in an enhanced and proprietary molecular formula.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Emerging Healthcare enters option agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it has entered into an option agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

12 Jan 2011

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Pro-Pharmaceuticals, the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that on December 17, 2010, Company representatives met with officials from the U.S. Food & Drug Administration to present its Phase III clinical development program for DAVANAT.

11 Jan 2011

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Amira Pharmaceuticals, Inc. announced today the publication of its findings in the Journal of Pharmacology and Experimental Therapeutics which describes the biologic effects and the characterization of AM095, a lysophosphatidic acid receptor 1 antagonist, in various in vitro and in vivo models of fibrotic disease.

6 Jan 2011

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Virginia Commonwealth University School of Medicine researchers have found that a significant increase of an enzyme in the blood vessels of pregnant women with preeclampsia may explain some of the symptoms associated with the condition, including hypertension, swelling and protein in the urine.

5 Jan 2011

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.

21 Dec 2010

RXi's dermal anti-scarring candidate selected to advance into development

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.

20 Dec 2010

BRIC researchers discover new protein that improves immune system

Researchers at BRIC, the University of Copenhagen, have discovered for the first time a protein normally found in the body that can act to prevent chronic tissue inflammation.

15 Dec 2010

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis dramatically ameliorates the clinical symptoms of the disease.

15 Dec 2010

Fibrin microthreads support mesenchymal stem cell growth

A research team at Worcester Polytechnic Institute has demonstrated the feasibility of a novel technology that a surgeon could use to deliver stem cells to targeted areas of the body to repair diseased or damaged tissue, including cardiac muscle damaged by a heart attack. The technique involves bundling biopolymer microthreads into biological sutures and seeding the sutures with stem cells. The team has shown that the adult bone-marrow-derived stem cells will multiply while attached to the threads and retain their ability to differentiate and grow into other cell types.

10 Dec 2010

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey.

10 Dec 2010

Systagenix launches new innovative website

Following the highly successful global launch of the new Corporate Identity, Systagenix has today unveiled its new innovative website - www.systagenix.com.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

Collagen News and Research

Latest Collagen News and Research

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

KineMed's fibrosis research program featured in Nature Medicine

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Endothelial cells may play a role in controlling cancer behavior: New study

Loyola offers new, nonsurgical treatment for Dupuytren's contracture

pH Advantage adds Pyranase to facial skin care line

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FDA accepts to review Fibrocell Science's azficel-T drug

Emerging Healthcare enters option agreement with OceanBASIS

Pro-Pharmaceuticals to begin DAVANAT Phase III development program following FDA approval

Findings of AM095 in various in vitro, in vivo models of fibrotic disease published in JPET

Increased amounts of MMP-1 enzyme may explain preeclampsia symptoms in pregnant women

Pro-Pharmaceuticals, Mount Sinai collaborate to evaluate anti-fibrotic effects of Galectin-targeting compounds

RXi's dermal anti-scarring candidate selected to advance into development

BRIC researchers discover new protein that improves immune system

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Fibrin microthreads support mesenchymal stem cell growth

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Systagenix launches new innovative website

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Collagen News and Research

Latest Collagen News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in